Skye Bioscience (SKYE) Competitors $2.17 0.00 (0.00%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$2.12 -0.05 (-2.12%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE vs. TNXP, PROK, ANNX, NGNE, PRTA, RNAC, INAB, CRVS, AVIR, and IMMPShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Tonix Pharmaceuticals (TNXP), ProKidney (PROK), Annexon (ANNX), Neurogene (NGNE), Prothena (PRTA), Cartesian Therapeutics (RNAC), IN8bio (INAB), Corvus Pharmaceuticals (CRVS), Atea Pharmaceuticals (AVIR), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Its Competitors Tonix Pharmaceuticals ProKidney Annexon Neurogene Prothena Cartesian Therapeutics IN8bio Corvus Pharmaceuticals Atea Pharmaceuticals Immutep Tonix Pharmaceuticals (NASDAQ:TNXP) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership. Do analysts rate TNXP or SKYE? Tonix Pharmaceuticals currently has a consensus price target of $585.00, suggesting a potential upside of 1,593.69%. Skye Bioscience has a consensus price target of $16.60, suggesting a potential upside of 664.98%. Given Tonix Pharmaceuticals' higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer TNXP or SKYE? Tonix Pharmaceuticals received 327 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 93.75% of users gave Skye Bioscience an outperform vote while only 60.53% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34260.53% Underperform Votes22339.47% Skye BioscienceOutperform Votes1593.75% Underperform Votes16.25% Does the media prefer TNXP or SKYE? In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Skye Bioscience. MarketBeat recorded 14 mentions for Tonix Pharmaceuticals and 10 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.23 beat Tonix Pharmaceuticals' score of 0.66 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 3 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TNXP or SKYE? Tonix Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Which has preferable earnings & valuation, TNXP or SKYE? Skye Bioscience has lower revenue, but higher earnings than Tonix Pharmaceuticals. Skye Bioscience is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.04M25.20-$116.66M-$1.96 thousand-0.02Skye BioscienceN/AN/A-$37.65M-$0.82-2.65 Is TNXP or SKYE more profitable? Skye Bioscience has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Skye Bioscience's return on equity of -45.78% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Skye Bioscience N/A -45.78%-37.44% Do insiders and institutionals have more ownership in TNXP or SKYE? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummarySkye Bioscience beats Tonix Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.22M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-2.658.6727.2119.96Price / SalesN/A262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book-12.766.597.074.69Net Income-$37.65M$143.75M$3.23B$248.14M7 Day Performance-10.88%0.68%0.68%0.91%1 Month Performance11.86%11.93%9.59%5.71%1 Year Performance-79.87%4.33%32.02%14.71% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience1.8222 of 5 stars$2.17flat$16.60+665.0%-78.2%$67.22MN/A-2.6511Positive NewsAnalyst RevisionTNXPTonix Pharmaceuticals3.3868 of 5 stars$39.20-3.6%$585.00+1,392.3%-68.9%$287.14M$10.04M-0.0150News CoverageGap DownPROKProKidney2.4749 of 5 stars$0.98+0.2%$5.00+410.2%-70.0%$286.84M$306K-1.783Positive NewsGap DownANNXAnnexon2.4306 of 5 stars$2.59-0.4%$12.50+382.6%-55.1%$284.16MN/A-2.4760Positive NewsAnalyst RevisionNGNENeurogene3.5356 of 5 stars$19.91-8.8%$44.60+124.0%-45.1%$283.96M$925K-4.5890Analyst ForecastGap UpPRTAProthena3.8395 of 5 stars$5.25-3.0%$31.50+500.0%-76.4%$282.59M$137.94M-2.28130Positive NewsShort Interest ↓Analyst RevisionHigh Trading VolumeRNACCartesian Therapeutics1.9084 of 5 stars$10.85-1.6%$43.00+296.3%-65.6%$281.60M$34.17M-0.2164Positive NewsAnalyst RevisionINABIN8bio3.576 of 5 stars$3.08-26.1%$180.00+5,744.2%-94.6%$279.58MN/A-4.1120Stock SplitShort Interest ↓Gap DownHigh Trading VolumeCRVSCorvus Pharmaceuticals2.8754 of 5 stars$4.04+3.3%$15.00+271.3%+104.8%$275.40MN/A-4.3430Positive NewsAnalyst RevisionAVIRAtea Pharmaceuticals3.3846 of 5 stars$3.21+0.9%$6.00+86.9%-15.1%$274.71MN/A-1.5570Positive NewsIMMPImmutep1.2907 of 5 stars$1.84-1.1%$7.00+280.4%-32.4%$268.71M$5.14M0.002,021 Related Companies and Tools Related Companies TNXP Alternatives PROK Alternatives ANNX Alternatives NGNE Alternatives PRTA Alternatives RNAC Alternatives INAB Alternatives CRVS Alternatives AVIR Alternatives IMMP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SKYE) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
